<DOC>
	<DOCNO>NCT01812213</DOCNO>
	<brief_summary>To investigate whether [ 18F ] NAV4694 positron emission tomography ( PET ) scan finding ability distinguish subject mild cognitive impairment ( MCI ) progress Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Beta-Amyloid Imaging With 18FNAV4694 Positron Emission Tomography ( PET ) Predicting Progression Alzheimer 's Disease ( AD ) Subjects With Mild Cognitive Impairment ( MCI )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Subject sign informed consent participate study continue give willing consent participation Age â‰¥ 55 year diagnosis MCI Educational level least 6 year Female subject childbearing potential ( &gt; 1 year postmenopausal surgically sterile ) Availability `` study partner '' assist complete rating scale duration study Cognitive complaint report subject confirm `` study partner '' Clinical Dementia Rating ( CDR ) global score = 0.5 Minimental state examination ( MMSE ) score 2430 Diagnostic Statistical Manual Mental Disorders , Version 4 , Text Revised ( DSMIVTR ) criteria dementia fulfil Has previously enrol study receive investigational product Has receive investigational product within 30 day prior screen Has receive diseasemodifying therapy could change amyloid brain deposition Has exceed yearly radioactive dose 30 mSv Has know allergy study drug constituent Has history alcohol abuse alcohol dependency 3 year prior study entry , alcoholic drug addict , determine investigator Has ongoing clinically significant ( judged investigator ) , metabolic disease could currently cause impaired memory ( e.g. , untreated thyroid disease , vitamin nutritional deficiency , chronic kidney , liver disease ) Memory impairment attribute disease condition early phase neurodegenerative syndrome Has parkinsonian movement disorder Use psychoactive medication would affect subject 's ability reliably perform neurocognitive test create uncertainty distinguish effect psychoactive medication subject 's underlying cognitive impairment ( e.g. , benzodiazepine , sedative , antipsychotic ) Has receive contrast material ( Xray , MRI ) radiopharmaceutical within 48 hour prior , therapeutic radiopharmaceutical ( e.g. , 131I ) within 10 day prior , radiopharmaceutical administration within 10 radioactive halflives prior administration investigational product administration substance plan within 7 day investigational product administration History major recurrent depressive disorder ( per DSMIVTR ) within last 5 year prior screen Has brain tumor intracranial lesion , disturbance cerebral spinal fluid circulation ( e.g. , normal pressure hydrocephalus ) , and/or significant history head trauma brain surgery Has sign major cerebrovascular disease , verify medical history and/or brain MRI Is schedule surgery and/or another invasive procedure within 7 day follow investigational product administration Has contraindication MRI examination , e.g. , metal implant , phobia , undergo MRI reason inability lie flat</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
</DOC>